

Index

- 23andme 5
 24M Technologies 151, 152
 525 Solutions, Inc. 255–256
- a**
- A123 Systems 105, 141–144, 151
 academic battery technology 129
 academic entrepreneurs 33, 34, 45, 52, 54, 170
 academic founders 34, 44, 45, 50, 52, 53
 academic inventors 154–159
 academic programs 172
 accelerators 9–10, 18, 131, 231, 232, 241, 250–251, 253
 activated charcoal 90, 92
 Advanced Inhalation Research 34, 35, 44, 45
 agile innovation teams 255
 air filtration 61, 92–97
 airplanes 138–139
 air purification approaches 90
 Alevo USA 147
 algae biofuel market 172, 173
 American Chemical Society (ACS) 14, 59, 168, 240
 angel funding 250
 angel investors 18, 47, 51, 53, 157, 241
 Aquion energy 143, 144
 attrition rates 214
 automotive companies 141, 173
- b**
- BASF 23, 106, 169, 178
 battery entrepreneurship
 licensing 162
 minimum-viable product (MVP) 132
 press relations (PR) and marketing strategies 162
 startups acceleration programs 132
 battery industry 129, 131, 159
 battery markets
 challenges 152–153
 financial challenges 154
 technical challenges 153–154
 battery materials 129–131, 144, 157
 battery startups 130–132, 139–152, 154, 155, 157–160, 163
 Bayh-Dole Act 130
 BD goals 122
 big pharma(s) 211–238, 254
 big pharma and open innovation model
 biotech companies 217
 cheminformatics-based startups 226
 compound providers 223
 contract research organizations (CROs) 221–222
 defined 217
 FDA approvals 216
 intellectual property (IP) 216
 medicinal chemistry-based biotechs 226
 novel business model 230–233
 patient associations and charities 220–221
 public administrations 221
 universities/research institutions 216–217
 venture capital 217–218
 X-ray diffraction studies 227–228
 biologics 215, 216
 biomedical field 33–56
 biomedical sector 33, 34, 47–49, 51, 53, 54

- biomedical ventures 51
 - bioreactors 2
 - biotech and pharma companies 217
 - Crispr Therapeutics 4
 - Editas Medicine 4
 - Intellia Therapeutics 4
 - Moderna Therapeutics 4
 - Unity Biotechnology 4
 - biotech startups 113, 159, 251
 - Blackrock 19
 - Boston Power 140, 141, 145, 150, 162
 - Brontide™ bio-butylene glycol 195
 - business model design 88
 - business-to-business (B2B) 23, 62, 87, 211
 - business-to-consumer (B2C) 23, 62, 87
 - business-to-government (B2G) 87
- C**
- Cadenza Innovation 140, 150, 162
 - capital requirements 176
 - capital-strapped public health funds 98
 - carbon-based sorbents 92
 - career opportunities 8, 241
 - The Carlyle Group 19
 - catalysts 111, 120, 128, 167, 176, 257
 - CatSci 254
 - cell voltages 132
 - charge and discharge rates 132
 - chemical industry 167–207, 209, 240, 248, 251, 253–255, 257, 258
 - chemical innovation 170, 239, 241
 - chemical sector 167–170, 173, 175, 176, 178, 180, 181, 186–188, 190–192, 194–198, 201–203, 206
 - chemical spills 96
 - chemical startups 179, 188, 241, 247, 251, 253, 258
 - chemical toxicity 168
 - chemistry curriculums 8
 - ChromaDex 8, 20, 21, 25–28, 30
 - co-inventorship 159
 - Cold Heavy Oil Production with Sand (CHOPS) 174, 181, 185, 189, 196, 198, 201, 204
 - commercial batteries 129
 - commercialization 21, 130
 - business-to-business (B2B) 23
 - business-to-consumer (B2C) 23
 - licensing deal 22
 - commercialization plan 68, 130, 249
 - commercial market 64, 67, 91, 133, 152, 163
 - commercial products 12, 26, 45, 63–65, 68, 129, 130, 172, 198, 227
 - commercial scale
 - best practices 194–195
 - company's growth trajectory 200
 - competitive threats 201, 202
 - financing 195–197
 - growth constraints 197
 - hidden landmine 201
 - insource vs. outsource 198–199
 - primary and secondary markets 197–198
 - commodity chemical market 195
 - Consumer Brand Company VCs 19
 - consumer chemicals 167
 - contract research organizations (CROs) 221–222, 254
 - corporate-sponsored academic research 46
 - corporate venture capitals (CVCs) 111–112
 - customer discovery and development
 - commercialization process 83
 - market demand and unmet needs 76–77
 - stakeholders in value chain 78–82
 - target industry's value chain 78
 - technology's uses 77
 - validation activities 83
 - validation model 83–85
 - customer feedback 72, 89, 255
 - customer interviews 88, 243, 246, 247
 - custom synthesis 223–226, 234, 235, 237
 - cycle life 132, 137, 139, 145, 147, 153
- d**
- defensive publication 161
 - diagnostics 1, 4–5, 8, 33, 58, 134
 - direct funding 120
 - discharge efficiency 132
 - disruptive innovations 1–2, 217, 235, 255
 - DNA synthesis 3
 - drones 134, 158
 - drug development process 42, 45, 231
- e**
- economies of scale
 - customer testimonials 189

defined 187
 direct sales vs distributors 191–192
 factors 187
 gaining customer traction 188–189
 market entry and initial sales 190–191
 measured growth 191
 pricing models 189–190
 strategic decisions 188
 testing and pivoting 192–194
 Edwards, David 34, 50, 53
 electric vehicles
 heavy duty utility vehicles, trucks, and buses 138
 light electric utility vehicles (LEV) 137–138
 passenger cars 137
 Endless West 3
 end users 63, 70–73, 77, 80–82, 90, 192
 energy and power density 132
 energy storage markets 129, 154
 airplanes 138–139
 electric vehicles 137
 grid energy storage and renewable energy 134–136
 home energy storage 136–137
 industrial batteries and back-up power 136
 portable electronics, drones and medical devices 134
 ships and boats 139
 Entrepreneurial Lead (EL) 243
 entrepreneurial startups 168, 169, 244
 entrepreneurial training 130, 131
 entrepreneurial ventures 167, 250
 entrepreneurs 2, 6–10, 16–18, 28, 30, 34, 38, 43, 50, 52, 53, 55, 61, 63, 65, 66, 73, 75, 77, 82, 83, 89, 103, 104, 109, 110, 113–121, 123–126, 130, 132, 162, 163, 167, 168, 170–173, 176, 179, 186, 188, 191–193, 198, 199, 206, 207, 209, 211, 222, 226, 230, 236, 239, 242–244, 250–252, 258, 262
 entrepreneurship education 244
 Envia Systems 146
 equipment manufacturers 142
 European Lead Factory (ELF) 232
 Evotec 254
 exploration and production (E&P) market 177

f

FDA approval 35, 47–49, 51, 55, 216
 fee-for-service model 211, 221, 225, 227, 235, 236
 flow batteries 130, 136, 151
 Fluidic Energy 145
 foie gras effect 154
 food and nutrition
 animal-free dairy products 2
 Endless West 3
 Impossible Foods 2
 Just Mayo 2
 Food Company VCs 19
 fuel cell development 173, 175, 185
 fuel cell entrepreneurs 104
 funding procedures 255
 funding strategy
 abundance and accessibility 156
 angel investments 157
 business plan competitions 156
 funding sources 155
 revenue streams 157
 traditional VC business model 155
 venture capital 158
 fund raising
 accelerators and incubators 18
 angel investors 18
 debt 18–19
 investment banks 20–21
 private equity 19
 self-funding 18
 strategic investment 19
 venture capital 19

g

gene editing 3, 4, 15
 Genomatica 3, 195
 Ginkgo Bioworks 3, 9
 Global Blue Technologies 256
 global warming 168
 Grail Diagnostics 5
 grid energy storage 134–136
 grid-scale batteries 134, 147
 Group-Purchase Organizations (GPOs) 97

h

Hanes, Justin 36, 47, 50, 52
 hard tech startups
 business models 105

- hard tech startups (*contd.*)
 - early-stage business development 119–120
 - financial clout 106
 - fundraising strategy
 - corporate venture capitals (CVCs) 111–112
 - early-stage investors 110
 - early-stage venture capitalists 110
 - employees and investors 107
 - financial outcomes 108
 - friends and family 109
 - fund life 112
 - investment opportunities 110
 - investors 108–109
 - late-stage venture capitalists 110
 - professional venture capitalists 110
 - return the fund 112–113
 - 10X return 118
 - investors
 - establish momentum 116, 117
 - and founders 104
 - large target market 115–116
 - market de-risking 117
 - partnering strategy 116
 - sales model and sales cycle 116
 - team value 115
 - technical de-risking 117
 - technology and customer value proposition 115
 - unit economics 116
 - partnerships 103
 - software scales 104
 - venture capital (VC) 105
 - healthcare fields 97
 - high-efficiency particulate air (HEPA) filters 92, 94
 - higher-energy lithium-ion battery cathodes 172
 - high-performance liquid chromatography (HPLC) 8, 218
 - high throughput screening model 2
 - home energy storage 136–137
 - hydrogen delivery system 182
 - hydrogen fuel cell storage 173
 - hydrogen-generation process 174
 - hydrogen storage 173
- i**
- I-Corps Diversity 244
 - I-Corps Nodes 245, 247
 - I-Corps Sites 244–248, 262
 - I-Corps Teams or National Cohorts 244–247
 - I2D2 233–235, 238
 - Impossible Foods 2, 23
 - incubators 9–10, 18, 156, 218, 221, 230–232, 257, 262
 - industrial gases 91, 167
 - Influit Energy 130, 131, 165, 166
 - in-licensed technology 44
 - innovation-driven company 182
 - innovation process 1, 2
 - intellectual property (IP) 216
 - management strategy 159–161
 - ownership 159
 - providers 131
 - misappropriation 123
 - Invention CEO
 - founder vs inventor 16
 - investment banks 20–21
 - investors 9, 18–21, 37, 47–55, 80–82, 103–120, 128, 132, 139, 140, 147, 148, 153–163, 169, 172, 179, 180, 184, 185, 190–192, 194–197, 202, 207, 229, 241, 248, 250, 253, 254
- j**
- Just Mayo 2
- k**
- Kala Pharmaceuticals 34, 36–37, 44, 47, 58
 - Kohlberg Kravis Roberts (KKR) 19
- l**
- lead-acid batteries 133, 136, 137, 145, 176
 - Lean Launchpad 131, 242, 248
 - licensing deal 22–23
 - light electric utility vehicles (LEV) 137–138
- m**
- Mari Signum Limited (MSL) 256
 - market conditions 184, 194, 198, 201
 - market delivery 181
 - market de-risking 117
 - market opportunity 117, 174, 176, 179, 185, 198, 207
 - market potential 103, 110, 120, 176
 - market segmentation 169–186, 194

market strategy 162, 163, 170, 178, 182, 193, 204
 Medicaid 97
 medical devices 33, 110, 133, 134, 209, 229
 Medicare 97
 metalloporphyrin moieties 91–92
 metal-modified carbons 90, 92
 micro-breakthrough experiments 91
 minimum viable product (MVP) 87, 105, 132, 262
 Moderna 4, 34, 37, 38, 44, 45, 47, 50
 Modern Meadow 3
 molecular modeling tools 224
 Moore, Geoffrey 252, 253
 multiple performance metrics 132

n

nanoelectrofuel flow battery technology 130
 nanofiber production method 94
 National Science Foundation (NSF) 242
 I-Corps program 242
 National Innovation Network 244
 Nelson, Donna 240
 new molecular entity (NME) 224
 new products and solutions 181
 nicotinamide riboside (NR) 26, 30
 non-dilutive funding 149, 157, 248–250, 262

o

ocean pollution 168
 oil market 193, 204–206, 262
 Open Innovation in Drug Discovery (OIDD) program 232
 Open Innovation model 211, 216–222
 organosilicate scaffolds 91

p

passenger cars 137
 patent breach 161
 patent process
 application 13
 CRISPR patent wars 15
 patent value 14
 PCT international patent 14
 pitfalls and traps 14
 prosecution 13
 provisional patent process 13
 publication 14

search and prior art 13
 structuring patent claims 13
 patent protection 48, 159, 161
 patient associations and charities 220–221
 Penicillin 10–11
 Perfect Day 2
 platform technology 40, 44–45, 53, 54, 117, 180, 197
 plug-and-play consumer ready product 22
 polymers 12, 91, 167, 242, 251, 256
 polypropylene 167
 portable electronics 132–134, 173
 portable Li-ion batteries 134
 Post-It 7, 11, 22
 press relations (PR) 162
 pricing models 189–190, 193
 principle investigator (PI) 246
 private equity 19, 128
 product development 8, 11, 17, 76, 77, 105, 111, 119, 120, 126, 158, 159, 170, 177, 182, 183, 204, 206, 240
 product process flow 88
 propylene 167, 176
 provisional patent process 13

q

quality control 7, 8, 25, 94

r

renewable energy 6, 129, 134–136
 research and development 8, 16, 37, 53, 68, 88, 131, 143, 146, 147, 150, 159, 169, 221, 240
 reverse engineering 160
 Ricardo, David 217
 right go-to-market strategy 182
 Robot as a Service (RaaS) 105
 Rossi, Derrick 37, 44, 50

s

saccharin 11
 Sakhti3 149
 sales growth 183, 191, 199
 scaling 104, 143, 168–171, 175–177, 179, 184–201, 203, 204, 206, 207, 255
 Schoellhammer, Carl 40, 50, 52
 scientific entrepreneurs 43, 168, 170, 206, 207
 scientific startups 170

- self-decontaminating material 89–100
 - self-funding 18
 - Senior Chemists Committee (SCC) 247
 - ships and boats 139
 - Sigilon 34, 38–40, 44, 45, 47, 50, 52
 - SiNode Systems 148
 - Small Business Innovation Research (SBIR) 148, 249, 257
 - sodium silicide 176, 177, 184, 185
 - Solazyme (TerraVia) 6
 - startup company 44, 239
 - academic founder 52
 - biomedical ventures 51
 - business plan 53
 - FDA approval process 51
 - founding CEO 52
 - high-impact journal, publishing of 50
 - in vivo validation 47–48
 - patent filed 48–49
 - seasoned co-founder 52
 - stationary storage batteries 136
 - strategic investment 19
 - strategic market segmentation
 - academic entrepreneurs 170
 - chemical business 175–177
 - demographic characteristics 170
 - existing problem/solutions 171–172
 - licensing vs. manufacturing 182–184
 - market assessment 184–186
 - market delivery 181
 - niche market strategy 178
 - pivot strategy 180–181
 - right go-to-market strategy 182
 - scientific entrepreneurs 170
 - strategic partnerships 145, 148, 149, 154, 158, 159
 - structure–activity relationship (SAR) 223
 - sulfuric acid 175, 176
 - Suono Bio 34, 40, 41, 45, 52, 53
 - sustainable/renewable chemistry 3
 - synthetic biology 3, 37
 - synthetic technologies 215
 - system integrators 131
- t**
- technical de-risking 117
 - technology discovery and development
 - commercial maturity 72
 - impact on technical concept 72
 - industry acceptance 73–76
 - origins of technology 69
 - performance characteristics 71
 - technology opportunities 73
 - technology transfer communication models 70
 - technology process flow 75, 88, 94
 - Technology Readiness Levels (TRLs) 75, 87
 - technology transfer
 - commercial product/service opportunities 63–65
 - communication models 70
 - entrepreneurship 63–68
 - research institutions 68
 - technology users 63, 69, 70
 - Teflon 11–12, 22
 - theory of comparative advantages 217
 - Theranos 5
 - ThruPore Technologies 257–258
 - trade-secret protection 160, 161
 - two-way communication pathway 69
 - typical battery technology firm 132
- u**
- Uber 138, 199
 - Unity Biotechnology 4
 - universal battery system 132
 - user/customer routine 88, 95
 - US pharmaceutical industry 253
- v**
- value proposition 115, 117, 119–121, 127, 169, 171, 174, 182, 183, 190–193, 202, 242, 245, 247, 249, 252, 257
 - Vegas, Arturo 38–39, 44, 45, 47, 50
 - venture capital (VC) 4, 19, 47, 105, 111–112, 132, 158, 169, 172, 196, 217–218, 250
 - firms 19, 36–38, 51, 52, 218, 222, 231
 - investors 169, 196
 - venture capitalists 18, 73, 110–112, 118, 179
 - Viagra 12
 - Viome 5
 - Vivtex 34, 41, 42, 45, 50, 53
 - von Erlach, Thomas 41, 42, 45, 50, 53
- y**
- yeast fermentation process 3
- z**
- Zymergen 3